Bristol Myers Squibb (NYSE: BMY) today announced updated data and first disclosure of results in chronic, refractory autoimmune diseases from the Phase 1 Breakfree-1 study (NCT05869955) of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback